Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBr.small Co.2 Regulatory News (BSC)

Share Price Information for Br.small Co.2 (BSC)

Share Price is delayed by 15 minutes
Get Live Data
50.55    0.00 (0.00%)
Bid:
49.60
Ask:
51.50
Spread: 1.90 (3.831%)
Market Cap: £193.32m
BSC Live PriceLast checked at - London Stock Exchange

Intraday Br.small Co.2 Share Chart

Interim Management Statement

19 Nov 2008 10:48

RNS Number : 4691I
British SmallerTechCompaniesVCT2PLC
19 November 2008
 

BRITISH SMALLER TECHNOLOGY COMPANIES VCT 2 PLC ("the Company")

INTERIM MANAGEMENT STATEMENT

For the quarter ended 30 September 2008

British Smaller Technology Companies VCT 2 plc presents its interim management statement for the quarter ended 30 September 2008. This constitutes the Company's second interim management statement for the financial year ending 31 December 2008, as required by the UK Listing Authority's Disclosure and Transparency Rule 4.3.

The unaudited net asset value per Ordinary share as at 30 September 2008 was 79.7 pence. This is a decrease of 3.9% over the net asset value of 82.9 pence per share at 30 June 2008.  The reduction is largely attributed to the recognition of the special and interim dividend paid to shareholders in September and totalling 4 pence per share. Hence the total return, calculated by reference to the net asset value plus cumulative dividends paid has increased from 94.9p per share at 30 June 2008 to 95.7 pence per share at 30 September 2008, an increase of 0.8%.  

In addition to the dividend, the last three months have seen the value of the AiM portfolio depressed given the market conditions and a £94k reduction in the portfolio has been recognised.  This represents a 6% reduction in the value of the AiM portfolio during the quarter. A review of the unquoted portfolio has identified some ups and downs, but minimal net impact on the value of the unquoted portfolio overall. The reduction in the value of the AiM portfolio has been offset by the recovery in the market value of the gilts, which have increased £110k during the period. At 30 September 2008, the Company held cash and Gilts representing 42.5% of the net asset value. 

This quarter has seen the inclusion of £164,000 in respect of the reclaim for irrecoverable VAT in line with the ruling by HMRC.

There has been no movement in the number of Ordinary shares, 16,641,257 Ordinary shares being in issue at both 31 December 2007 and 30 June 2008.

The Company has completed one investment in the quarter, being a £52,000 follow on equity investment in Manchester based computer chip designer Silistix Limited Disposals of £3,500 related to the scheduled loan repayments made by RMS Group Limited.

Net assets at 30 September 2008 comprised the following:

£000

% of net assets

Unquoted investments at fair value

5,815

43.8

Quoted investments at bid price

1,519

11.5

Total venture capital investments

7,334

55.3

Cash and cash equivalents

5,633

42.5

Other net current assets

295

2.2

Net assets

13,262

100.0

The net asset value per Ordinary share at 30 September 2008 was 79.7 pence. The net asset value remains significantly in excess of the current share price.

The ten largest investments by valuation at 30 September 2008 were as follows:

£000

% of net assets

Digital Healthcare

1,650

12.5

Immunobiology

850

6.4

Silistix

719

5.4

Primal Pictures

642

4.8

Pressure Technologies

520

3.9

ART

484

3.7

RMS

435

3.3

Cater Plus

345

2.6

DxS

320

2.4

Harvey Jones

278

2.1

Top ten investments

6,243

47.1

Other investments

1,091

8.2

Total venture capital investments

7,334

55.3

Quoted investments are carried at bid price at 30 September 2008. Unquoted investment are carried at fair value as at 30 September 2008 as determined by the directors.

During the three months ended 30 September 2008 the following significant investment transactions took place (all companies are unquoted except where otherwise indicated):

Follow-on Investments:

Name of company:

Business activity:

Amount invested £000

Silistix Ltd

Silicon chip design

52

52

In this period the Company has seen its underlying net asset value increase by 0.8 pence per share after the payment of an interim dividend of 2 pence per share and a special dividend of 2 pence share. It is pleasing to note that the residual net asset value has both increased and currently comprises 42.5% in gilts and cash.

With the principal investments in the portfolio all having secured funding with little exposure to financial leverage the portfolio is itself well placed to take advantage of expansion opportunities as they arise.

There has been a marked increase in the number of investment opportunities being presented. The Company's liquidity is good but your board will be seeking to increase this through a non-prospectus top up offer early in the New Year.

 

19 November 2008

For further information please contact:

David Hall YFM Private Equity Tel: 0161 832 7603

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSGUGMCGUPRGUB
Date   Source Headline
24th Oct 20249:00 amRNSUpdate on Offers
24th Oct 20249:00 amRNSUpdate on Offers
17th Oct 20241:00 pmRNSPublication of Circular
17th Oct 202412:45 pmRNSPublication of a Prospectus
17th Oct 202412:45 pmRNSPublication of a Prospectus
27th Sep 20247:34 amRNSTransaction in Own Shares
12th Sep 20247:00 amRNSHalf-year Report
10th Sep 20242:00 pmRNSUpdate on new combined offer for subscription
20th Aug 20247:00 amRNSStatement re NAV and Proposed Fundraising
20th Aug 20247:00 amRNSStatement re NAV and Proposed Fundraising
28th Jun 20249:43 amRNSPayment of dividend and issue of shares
25th Jun 20247:00 amRNSTransaction in Own Shares
14th Jun 202412:30 pmRNSInterim Management Statement
13th Jun 202410:03 amRNSResult of AGM
3rd Apr 20248:04 amRNSDirector/PDMR Shareholding
3rd Apr 20248:04 amRNSDirector/PDMR Shareholding
3rd Apr 20247:57 amRNSIssue of Equity and Close of Offers
26th Mar 202411:10 amRNSTransaction in Own Shares and Total Voting Rights
21st Mar 20247:40 amRNSAppointment of non-executive Director
20th Mar 202412:00 pmRNSPublication of Supplementary Prospectus
20th Mar 202412:00 pmRNSPublication of Supplementary Prospectus
15th Mar 202412:15 pmRNSAnnual Financial Report
16th Feb 20243:52 pmRNSClose of Offers to New Applications
16th Feb 20243:51 pmRNSClose of Offers to New Applications
30th Jan 20249:26 amRNSDirector/PDMR Shareholding
30th Jan 20249:24 amRNSDirector/PDMR Shareholding
30th Jan 20249:24 amRNSIssue of Equity
18th Dec 20234:04 pmRNSTransaction in Own Shares
13th Dec 20234:00 pmRNSStrategy/Company/Ops Update
13th Dec 20234:00 pmRNSOffer Update
24th Nov 20237:00 amRNS3rd Quarter Results
3rd Nov 20239:40 amRNSPayment of dividend and issue of equity
24th Oct 20231:20 pmRNSOffer Update
24th Oct 20231:19 pmRNSOffer Update
6th Oct 202310:19 amRNSOffer Update
6th Oct 202310:17 amRNSOffer Update
27th Sep 20238:21 amRNSOffer Update
26th Sep 20238:16 amRNSTransaction in Own Shares
20th Sep 202312:30 pmRNSPublication of a Prospectus
20th Sep 202312:30 pmRNSPublication of a Prospectus
13th Sep 20237:00 amRNSHalf-year Report
2nd Aug 202310:25 amRNSNew combined offer for subscription
2nd Aug 202310:25 amRNSNew combined offer for subscription
27th Jun 20237:46 amRNSTransaction in Own Shares
26th Jun 202310:57 amRNSDirector/PDMR Shareholding
26th Jun 202310:56 amRNSPayment of Dividend and Issue of Equity
16th Jun 202312:00 pmRNS1st Quarter Results
15th Jun 20233:17 pmRNSResult of Meeting
15th Jun 20233:16 pmRNSResult of AGM
4th Apr 20233:25 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.